Sunshine Biopharma Inc
NASDAQ:SBFM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
J
|
Jiangsu Baoli International Investment Co Ltd
SZSE:300135
|
CN |
|
Allpark Empreendimentos Participacoes e Servicos SA
BOVESPA:ALPK3
|
BR |
|
MRV Engenharia e Participacoes SA
BOVESPA:MRVE3
|
BR |
Sunshine Biopharma Inc
Other Liabilities
Sunshine Biopharma Inc
Other Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sunshine Biopharma Inc
NASDAQ:SBFM
|
Other Liabilities
$596.8k
|
CAGR 3-Years
-2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Other Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Other Liabilities
$24.2m
|
CAGR 3-Years
8%
|
CAGR 5-Years
0%
|
CAGR 10-Years
9%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Other Liabilities
$9.6m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
25%
|
CAGR 10-Years
58%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Other Liabilities
CA$75.9k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Other Liabilities
$6.5m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sunshine Biopharma Inc
Glance View
Sunshine Biopharma, Inc. engages in the research, development, and commercialization of oncology and antiviral drugs. The company is headquartered in Pointe-Claire, Quebec and currently employs 3 full-time employees. The company went IPO on 2008-08-15. In addition, the Company is engaged in the development and commercialization of science-based nutritional supplements. The Company’s drug development operations include SBFM-PL4 Anti-Coronavirus Treatment and Adva-27a Anticancer Drug. The firm is engaged in the development of its Anti-Coronavirus compound, SBFM-PL4. The company is advancing the development of two compounds in parallel with its SBFM-PL4. The Company’s drug development activities have focused on the development of a small molecule, Adva-27a for the treatment of aggressive forms of cancer. A Topoisomerase II inhibitor, Adva-27a has been shown to be effective at destroying Multidrug Resistant Cancer cells, including Pancreatic Cancer cells, Breast Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells.
See Also
What is Sunshine Biopharma Inc's Other Liabilities?
Other Liabilities
596.8k
USD
Based on the financial report for Dec 31, 2025, Sunshine Biopharma Inc's Other Liabilities amounts to 596.8k USD.
What is Sunshine Biopharma Inc's Other Liabilities growth rate?
Other Liabilities CAGR 3Y
-2%
Over the last year, the Other Liabilities growth was -20%. The average annual Other Liabilities growth rates for Sunshine Biopharma Inc have been -2% over the past three years .
